Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
Chen
Z
Z
Aston
E
E
Yu
M K
MK
D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007527:Isoenzymes / Q000172:deficiency; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000201:enzymology*; D008875:Middle Aged; D017027:Protein Tyrosine Phosphatases / Q000172:deficiency*; D011505:Protein-Tyrosine Kinases / Q000172:deficiency*; D011518:Proto-Oncogene Proteins / Q000172:deficiency; D013256:Steroids / Q000009:adverse effects / Q000627:therapeutic use; D051746:ZAP-70 Protein-Tyrosine Kinase
D000970:Antineoplastic Agents; D007527:Isoenzymes; D011518:Proto-Oncogene Proteins; D013256:Steroids; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; C490429:ACP1 protein, human; D017027:Protein Tyrosine Phosphatases